Hangzhou biotech MindRank says its lead candidate, MDR-001, has reached Phase III trials after roughly four and a half years of development and about $23 million in cumulative research spending. The oral small-molecule GLP-1 receptor agonist targets obesity and diabetes, markets currently dominated by injectable medicines. A pill could be easier to distribute and cheaper to manufacture, making the class highly competitive.
MindRank says its Molecule Arts platform combines biological, chemical, computational and clinical data to accelerate drug research. The company has also secured three investigational new drug clearances in China and the US and nominated five preclinical candidates. Its claims, however, come from company announcements; clinical data has not been published or peer-reviewed.
The reported cost is not directly comparable with conventional estimates that include failed programmes, and Chinese trials can cost less than those in the US or Europe. Phase III obesity studies require large patient populations and long follow-up, so the hardest and most expensive test remains ahead. Results will show whether AI shortened development without compromising efficacy or safety.
https://thenextweb.com/news/mindrank-ai-drug-discovery-glp1-phase-three
oxhak / Ox HaK
npub1sx…dz7z7
2026-08-26 10:06:08 UTC
Author Public Key
npub1sxexewvzysc3affq4yzzh7w8e3udyujap2vlj7t6lkdg5dvhp24q4dz7z7Published at
2026-08-26 10:06:08 UTCEvent JSON
{
"id": "167ae017d8057e3f0856c8fbf3011105aa5a0a3fc77475f2fb27e0bf51d5c8f8",
"pubkey": "81b26cb98224311ea520a9042bf9c7cc78d2725d0a99f9797afd9a8a35970aaa",
"created_at": 1787738768,
"kind": 1,
"tags": [],
"content": "Hangzhou biotech MindRank says its lead candidate, MDR-001, has reached Phase III trials after roughly four and a half years of development and about $23 million in cumulative research spending. The oral small-molecule GLP-1 receptor agonist targets obesity and diabetes, markets currently dominated by injectable medicines. A pill could be easier to distribute and cheaper to manufacture, making the class highly competitive.\n\nMindRank says its Molecule Arts platform combines biological, chemical, computational and clinical data to accelerate drug research. The company has also secured three investigational new drug clearances in China and the US and nominated five preclinical candidates. Its claims, however, come from company announcements; clinical data has not been published or peer-reviewed.\n\nThe reported cost is not directly comparable with conventional estimates that include failed programmes, and Chinese trials can cost less than those in the US or Europe. Phase III obesity studies require large patient populations and long follow-up, so the hardest and most expensive test remains ahead. Results will show whether AI shortened development without compromising efficacy or safety.\n\nhttps://thenextweb.com/news/mindrank-ai-drug-discovery-glp1-phase-three",
"sig": "fc34e5a2d938a5eb3e880f61a63480f8b5857a274b333a219e278b3e1547044901416e859b91ea0f8ef7ea3decdcc583fbcc0449eb45bf843695ddd8d9470e68"
}